Press Releases
Press Release filters
Sign up to receive updates from mdxhealth
Click the button below to fill in your contact information and receive updates from mdxhealth.
MDxHealth : Extraordinary General Shareholders’ Meeting
IRVINE, CA, and HERSTAL, BELGIUM, 20 June 2016 -MDxHealth SA (NYSE Euronext: MDXH.BR), held its Extraordinary General Meeting of S
MDxHealth Announces European Urology Editorial Supporting SelectMDx Use in Detecting Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – June 16, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today the publication of an editori
MDxHealth (R): Grants QIAGEN Rights to MSP Technology for QIAsure Methylation Test for Cervical Cancer Risk
IRVINE, CA, and HERSTAL, BELGIUM – June 15, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it has granted a non-exc
MDxHealth Holds Capital Markets Day in New York City
Key Opinion Leaders Highlight MDxHealth’s Commercial Portfolio IRVINE, CA, and HERSTAL, BELGIUM – June 14, 2016 – MDxHealth SA (
MDxHealth Secures First Reimbursement Coverage for SelectMDx
IRVINE, CA, and HERSTAL, BELGIUM – June 14, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it has secured the first
Annual General Shareholders’ Meeting
Irvine, CA, and Herstal, BELGIUM – May 27, 2016 – MDxHealth SA (Euronext: MDXH), held today its Annual General Shareholders’ Meeti
MDxHealth (R): Disclosure of the Number of Outstanding Voting Securities
IRVINE, CA and HERSTAL, BELGIUM, May 20, 2016 – MDxHealth SA (NYSE Euronext: MDXH) (“MDxHealth”) announced today, pursuant to Arti
MDxHealth’s ConfirmMDx Stratifies Risk for Aggressive Prostate Cancer
Multicenter validation study published in the journal The Prostate IRVINE, CA, and HERSTAL, BELGIUM – May 9, 2016 – MDxHealth SA
MDxHealth Announces Positive Data Supporting Prognostic Value of ConfirmMDx and SelectMDx for Prostate Cancer
Data are Presented at the American Urological Association Annual Meeting, 6-10 May 2016, San Diego IRVINE, CA, and HERSTAL, BELG
MDxHealth Provides First Quarter 2016 Business Update
Revenue Increased 66% Over First Quarter 2015 IRVINE, CA, and HERSTAL, BELGIUM – May 3, 2016 – MDxHealth SA (Euronext: MDXH.BR) t
MDxHealth’s SelectMDx Study Published in European Urology
Data validates ‘liquid biopsy’ test’s ability to identify men at risk for aggressive cancer IRVINE, CA, and HERSTAL, BELGIUM –
MDxHealth Partners with Andros Men’s Clinic to Offer SelectMDx for Prostate Cancer
IRVINE, CA, and HERSTAL, BELGIUM – March 29, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with A
MDxHealth Launches SelectMDx “Liquid Biopsy” Test in the United States
Non-invasive, urine-based prostate cancer assay available as a laboratory developed test IRVINE, CA, and HERSTAL, BELGIUM – Mar
MDxHealth Presents SelectMDx(TM) Results from Multicenter Validation Study at the 2016 Annual EAU Congress
SelectMDx awarded best poster presentation by EAU’s Scientific Congress Office IRVINE, CA, and HERSTAL, BELGIUM – March 14, 2016
MDxHealth Appoints Global Commercial Team for SelectMDx
IRVINE, CA, and HERSTAL, BELGIUM – March 9, 2016 – MDxHealth SA (Euronext: MDXH.BR) announced today that it has appointed a global
MDxHealth Announces Inclusion of ConfirmMDx in 2016 NCCN Guidelines for Prostate Cancer Early Detection
IRVINE, CA, and HERSTAL, BELGIUM – March 2, 2016 – MDxHealth SA (Euronext: MDXH.BR), today announced that its ConfirmMDx® for Pro
MDxHealth Reports Fourth Quarter and Fiscal Year 2015 Results
Full Year ConfirmMDx Revenue up 62% Compared to Full Year 2014 IRVINE, CA, and HERSTAL, BELGIUM – 7:00 AM, February 18, 2016 – M
MDxHealth Announces Conference Participation for First Half 2016
IRVINE, CA, and HERSTAL, BELGIUM – January 28, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it will be participat
MDxHealth Receives 2016 Frost & Sullivan Global Prostate Cancer Diagnostics Technology Innovation Award
IRVINE, CA, and HERSTAL, BELGIUM – January 21, 2016 – MDxHealth SA (Euronext: MDXH.BR) announced today that it received the 2016 F
MDxHealth Analytical Validation Study on AssureMDx for Bladder Cancer Published in The Journal of Urology
Liquid Biopsy Test Delivers High Negative Predictive Value of 99.2% for Bladder Cancer IRVINE, CA, and HERSTAL, BELGIUM, January
